Sign in
4

Changes in Ownership

Stoke Therapeutics, Inc. Filed Acc 0001966716-25-000008

GENERAL COUNSEL & CORP SEC sold 9,803 shares at an average $31.25 ($306,322)

  • GENERAL COUNSEL & CORP SEC acquired 6,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Allan Jonathan GENERAL COUNSEL & CORP SEC 2025-12-03 Option exercise 10b5-1 +6,000 25,612 D: show line 1 in the form
Allan Jonathan GENERAL COUNSEL & CORP SEC 2025-12-04 Sale 10b5-1 −824 $30.76 $25,349 24,788 D: show line 2 in the form
Allan Jonathan GENERAL COUNSEL & CORP SEC 2025-12-04 Sale 10b5-1 −194 $31.32 $6,075 24,594 D: show line 3 in the form
Allan Jonathan GENERAL COUNSEL & CORP SEC 2025-12-05 Sale 10b5-1 −1,004 $31.33 $31,456 23,590 D: show line 4 in the form
Allan Jonathan GENERAL COUNSEL & CORP SEC 2025-12-05 Sale 10b5-1 −5,437 $31.08 $168,997 18,153 D: show line 5 in the form
Allan Jonathan GENERAL COUNSEL & CORP SEC 2025-12-05 Sale 10b5-1 −2,344 $31.76 $74,445 15,809 D: show line 6 in the form
Open-market sales · 9,803 sh · avg $31.25 · $306,322

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Allan Jonathan GENERAL COUNSEL & CORP SEC 2025-12-03 Option exercise · Performance Stock Units 10b5-1 −6,000 0 D: show line 7 in the form
Loading xslF345X05/form4-12062025_011219.xml…